Polymorph forms of reboxetine and its salts
A reboxetine-based pharmaceutical composition, formulated with specific polymorphs and excipients, addresses the variability and tolerability issues of current narcolepsy treatments, enhancing efficacy and reducing cataplexy attacks effectively.
WO2026143062A1PCT designated stage Publication Date: 2026-07-02AXSOME THERAPEUTICS INC +1
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- AXSOME THERAPEUTICS INC
- Filing Date
- 2025-12-22
- Publication Date
- 2026-07-02
AI Technical Summary
Technical Problem
Current treatments for narcolepsy, particularly narcolepsy with cataplexy, suffer from variability in efficacy, tolerability issues, and the need for DEA scheduling, limiting their effectiveness and accessibility.
Method used
A pharmaceutical composition comprising reboxetine free base or its pharmaceutically acceptable salts, such as reboxetine mesylate, formulated into a tablet dosage form with specific polymorphs and excipients to enhance therapeutic efficacy and patient tolerability.
Benefits of technology
The formulation provides a consistent and effective reduction in cataplexy attacks, improving cognitive, psychological, and social functioning while minimizing side effects and regulatory constraints.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2025061036_02072026_PF_FP_ABST
Abstract
Dosage forms containing reboxetine having improved purity, and their therapeutic uses, are described herein.
Need to check novelty before this filing date? Find Prior Art